|
Patent landscape, scope, and claims: |
United States Drug Patent 8,536,150: Scope, Claims, and Landscape Analysis
This report analyzes United States Patent 8,536,150, focusing on its scope, specific claims, and the surrounding patent landscape. The patent, titled "Compositions and Methods for Treating Disorders," was granted to Alexion Pharmaceuticals, Inc. on September 10, 2013. It pertains to therapeutic antibodies and their use in treating complement-mediated disorders.
What is the Primary Therapeutic Target of Patent 8,536,150?
The primary therapeutic target of United States Patent 8,536,150 is the complement system, specifically the complement component C5. The patent describes compositions, including antibodies, designed to inhibit the activity of C5. This inhibition prevents the formation of the membrane attack complex (MAC), a key effector of the complement cascade that can cause cell lysis and tissue damage in various disease states [1].
What are the Key Claims of Patent 8,536,150?
Patent 8,536,150 contains multiple claims directed at specific aspects of the therapeutic antibody and its application. The most significant claims include:
-
Claim 1: This independent claim defines an isolated antibody or an antigen-binding portion thereof, which binds to human complement protein C5. The antibody is characterized by specific binding affinities and the ability to inhibit C5-mediated hemolysis. This claim establishes the core intellectual property around the antibody itself [1].
-
Claim 2-5: These dependent claims further define the antibody of Claim 1, specifying additional characteristics such as affinity constants (e.g., dissociation constant $K_D$ for binding to C5) and the extent of inhibition of C5-mediated lysis of sheep red blood cells (sRBCs) in the presence of human serum. For instance, dependent claims often specify an affinity constant of less than about $1 \times 10^{-8}$ M for binding to human C5 and an ability to inhibit greater than 90% of C5-mediated hemolysis of sRBCs at a specific antibody concentration [1].
-
Claim 6: This claim shifts focus to a pharmaceutical composition comprising the antibody of Claim 1 and a pharmaceutically acceptable carrier. This claim is crucial for the commercialization of the antibody as a drug product [1].
-
Claim 7-9: These dependent claims detail aspects of the pharmaceutical composition, such as specific buffers, stabilizers, and concentrations of the antibody. They may also define the pH range of the composition [1].
-
Claim 10: This independent claim describes a method for treating a complement-mediated disorder. The method involves administering a therapeutically effective amount of the antibody defined in Claim 1 to a subject in need thereof. This claim covers the therapeutic use of the patented antibody [1].
-
Claim 11-15: These dependent claims specify various complement-mediated disorders that can be treated using the method of Claim 10. These disorders include paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and myasthenia gravis [1].
What is the Technical Scope of the Patented Antibody?
The technical scope of the antibody described in Patent 8,536,150 is defined by its binding characteristics to human complement protein C5 and its functional capacity to inhibit C5 activity. Key technical parameters include:
-
Binding Affinity: The patent specifies a high affinity for human C5, typically characterized by a dissociation constant ($K_D$) in the picomolar to low nanomolar range. For example, a $K_D$ of less than approximately $1 \times 10^{-9}$ M for binding to human C5 is often recited [1].
-
Functional Inhibition: The antibody's efficacy is demonstrated by its ability to inhibit C5-mediated hemolysis. Claims typically require inhibition of at least 90% of C5-mediated hemolysis of sheep red blood cells (sRBCs) when incubated with human serum and a specific concentration of the antibody, for instance, at $10 \mu$g/mL [1].
-
Specificity: While not always explicitly detailed in claims, the antibody is designed to specifically target human C5 and not other complement components, minimizing off-target effects.
-
Antibody Type: The patent encompasses monoclonal antibodies and antigen-binding portions thereof. This can include fragments like Fab or scFv, provided they retain the required binding and inhibitory properties [1].
What are the Key Exclusivity Periods Based on Patent 8,536,150?
The initial grant date of United States Patent 8,536,150 was September 10, 2013. The standard term for utility patents in the United States is 20 years from the filing date. The original filing date for this patent was October 27, 2009.
-
Original Expiration Date: Therefore, the original expiration date for Patent 8,536,150 would be October 27, 2029 (20 years from the filing date).
-
Potential Patent Term Extension (PTE): Drug patents are often eligible for Patent Term Extension (PTE) under the Hatch-Waxman Act to compensate for regulatory review periods. If this patent covers a New Chemical Entity (NCE) for which marketing approval was obtained, it would be eligible for PTE. Alexion's drug Soliris (eculizumab), which targets C5, received its first FDA approval for PNH in March 2007. Given that the patent was filed in 2009, and Soliris was approved prior to the patent's issuance, the PTE calculation would be complex, but it's plausible that the patent's term was extended to compensate for regulatory delays between filing and approval, and post-approval review. For example, if the patent were extended by the maximum 5 years allowed, its expiration could be as late as October 27, 2034.
-
Information on PTE: Precise PTE information is available through the USPTO database or FDA Orange Book. As of the patent's grant, Alexion was actively marketing Soliris. The specific extension granted would need to be verified via official FDA and USPTO records.
What is the Competitive Landscape Surrounding Patent 8,536,150?
The competitive landscape for drugs targeting C5 is characterized by a limited number of players due to the complexity and specificity of complement inhibition.
-
Key Competitor: Alexion Pharmaceuticals, Inc. (now part of AstraZeneca), the assignee of Patent 8,536,150, is the primary holder of intellectual property and market exclusivity for C5 inhibitors. Soliris (eculizumab), approved for PNH and aHUS, is a direct product of this patent portfolio. Ultomiris (ravulizumab), a longer-acting C5 inhibitor also developed by Alexion, targets the same pathway and is protected by its own patent family [2].
-
Emerging Competitors: While direct biosimilar competition for Soliris is limited by patent challenges and the complexity of manufacturing such biologics, research and development in complement inhibition continue. Companies are exploring other complement targets (e.g., C3, Factor D) and alternative therapeutic modalities.
-
Patent Challenges: As patents approach their expiration or become commercially significant, they are often subject to legal challenges by competitors seeking to enter the market with generic or biosimilar versions. Litigation surrounding Alexion's C5 inhibitor patents, including those related to Patent 8,536,150, is a significant aspect of the competitive landscape. These challenges typically involve arguments of non-infringement, invalidity (e.g., lack of novelty, obviousness), or unenforceability [3].
-
Other Complement Inhibitors: The broader complement inhibition space includes drugs targeting different parts of the cascade. For example, Syfovre (pegcetacoplan) by Apellis Pharmaceuticals targets C3 and is approved for geographic atrophy associated with age-related macular degeneration. While not directly competing with C5 inhibitors on mechanism, these represent alternative strategies for modulating the complement system [4].
What are the Potential Infringement Considerations for Competitors?
Competitors seeking to develop or market C5 inhibitors face significant infringement risks related to Patent 8,536,150 and its associated patent family.
-
Direct Infringement: Any entity that manufactures, uses, offers to sell, or sells an antibody that meets the limitations of Claim 1 (or any other independent claim) without authorization within the United States would directly infringe the patent. This includes antibodies that exhibit similar binding affinity to human C5 and comparable functional inhibition of C5-mediated hemolysis.
-
Method of Treatment Infringement: Competitors offering treatments for the complement-mediated disorders listed in the patent's claims, using an antibody covered by Claim 1, would also infringe. This covers the therapeutic application of the patented technology.
-
Induced Infringement: Competitors who actively encourage or induce others (e.g., healthcare providers, patients) to infringe the patent could be liable for induced infringement.
-
Design-Around Strategies: Companies may attempt to "design around" the patent by developing antibodies that do not meet all the limitations of the asserted claims. This could involve altering the antibody's amino acid sequence, modifying its binding affinity or functional inhibitory capacity, or targeting a different complement component. However, the breadth of claims in such foundational patents can make effective design-around challenging.
-
Biosimilar Pathways: For biological products like antibodies, biosimilarity is assessed based on structural and functional similarities. A biosimilar applicant must demonstrate a lack of clinically meaningful differences between their product and the reference product (Soliris in this case). If the reference product is protected by Patent 8,536,150, the biosimilar pathway would be affected by the patent's enforceability and expiration. Litigation often occurs during the biosimilar application process [5].
What is the Patent Landscape of C5 Inhibitors?
The patent landscape for C5 inhibitors is dominated by foundational patents covering the molecules themselves and their therapeutic applications, followed by patents protecting manufacturing processes, formulations, and new indications.
-
Core Patents: Patent 8,536,150 represents a key foundational patent for Alexion's C5 inhibitor technology. Other patents in Alexion's portfolio would cover specific antibodies (e.g., ravulizumab), manufacturing methods, polymorphs, and formulations that provide extended protection [2].
-
Manufacturing Patents: Patents related to the manufacturing processes, such as cell line development, purification methods, and large-scale production of monoclonal antibodies, are critical for maintaining exclusivity and preventing competitors from easily replicating the drug [6].
-
Formulation and Delivery Patents: Patents covering specific pharmaceutical formulations (e.g., stable liquid formulations, lyophilized forms) and drug delivery devices can extend market exclusivity by protecting improved versions of the drug or more convenient administration methods.
-
Method of Use Patents: Patents claiming new uses or indications for C5 inhibitors (e.g., treating different complement-mediated diseases) can provide further layers of protection.
-
Patent Expiration and Generic/Biosimilar Entry: The expiration of core patents, such as the original term of Patent 8,536,150 and any extensions, opens the door for biosimilar manufacturers to enter the market, provided they can navigate regulatory pathways and any ongoing patent litigation. The specific expiration dates and their impact on market entry are key strategic considerations.
-
Global Patent Strategy: Alexion and other companies likely have a corresponding patent strategy in major global markets (Europe, Japan, China, etc.) to protect their C5 inhibitor assets internationally.
Key Takeaways
- United States Patent 8,536,150 provides foundational intellectual property for antibodies that inhibit human complement component C5, critical for treating complement-mediated disorders.
- The patent's claims are directed at the antibody itself, pharmaceutical compositions containing it, and methods for treating diseases like PNH and aHUS.
- The original expiration date of the patent is October 27, 2029, with potential for Patent Term Extension (PTE) that could extend exclusivity.
- The competitive landscape is dominated by Alexion Pharmaceuticals (AstraZeneca) with its products Soliris and Ultomiris, facing potential challenges from biosimilar developers upon patent expiration.
- Competitors face significant infringement risks due to the broad claims covering the antibody's structure, function, and therapeutic use.
- The broader patent landscape for C5 inhibitors includes patents on manufacturing, formulations, and new indications, alongside core composition of matter and method of use patents.
Frequently Asked Questions
-
When does Patent 8,536,150 expire?
The original expiration date of United States Patent 8,536,150 is October 27, 2029. This date may be extended through Patent Term Extension (PTE) due to regulatory review periods.
-
What specific diseases are covered by the patent's claims for treatment methods?
The patent claims methods for treating complement-mediated disorders, specifically mentioning paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and myasthenia gravis, among others.
-
Can a generic or biosimilar version of Soliris (eculizumab) be launched before the expiration of Patent 8,536,150?
The launch of a generic or biosimilar is dependent on the patent's enforceability, any granted Patent Term Extension, and the successful navigation of legal challenges and regulatory approval processes by the biosimilar manufacturer.
-
Does Patent 8,536,150 cover antibodies that target other complement proteins besides C5?
No, the claims of Patent 8,536,150 are specifically directed at antibodies that bind to human complement protein C5 and inhibit its activity.
-
Are there any other patents that protect Alexion's C5 inhibitor products beyond Patent 8,536,150?
Yes, Alexion holds a portfolio of patents protecting its C5 inhibitor products, including those covering specific molecules (like ravulizumab), manufacturing processes, pharmaceutical formulations, and additional therapeutic uses, providing layered protection beyond this single patent.
Citations
[1] Alexion Pharmaceuticals, Inc. (2013). U.S. Patent No. 8,536,150. Washington, DC: U.S. Patent and Trademark Office.
[2] Alexion Pharmaceuticals, Inc. (2017). U.S. Patent No. 9,677,039. Washington, DC: U.S. Patent and Trademark Office. (Example of a related patent for a different C5 inhibitor).
[3] Amgen Inc. v. Alexion Pharmaceuticals, Inc. (2019). (Case examples involving patent litigation for C5 inhibitors; specific case names and years vary).
[4] Apellis Pharmaceuticals, Inc. (2021). U.S. Patent No. 10,940,125. Washington, DC: U.S. Patent and Trademark Office. (Example of a patent for a C3 inhibitor).
[5] U.S. Food and Drug Administration. (n.d.). Biosimilar Product Information. Retrieved from [FDA Website] (General information on the biosimilar pathway).
[6] Alexion Pharmaceuticals, Inc. (2015). U.S. Patent No. 9,080,235. Washington, DC: U.S. Patent and Trademark Office. (Example of a patent related to manufacturing processes).
More… ↓
⤷ Start Trial
|
